- Home
- GWRS vs ABEO Comparison
GWRS vs ABEO Comparison
Compare GWRS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GWRS | ABEO |
|---|---|---|
| Founded | 2003 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 280.2M |
| IPO Year | 2008 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GWRS | ABEO |
|---|---|---|
| Price | $9.24 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.60 | ★ $18.20 |
| AVG Volume (30 Days) | 48.3K | ★ 895.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | N/A | ★ 38.74 |
| EPS | 0.15 | ★ 1.35 |
| Revenue | ★ $41,914,000.00 | $2,998,000.00 |
| Revenue This Year | $7.96 | N/A |
| Revenue Next Year | $9.11 | $1,589.77 |
| P/E Ratio | $60.07 | ★ $3.66 |
| Revenue Growth | 8.51 | ★ 258.18 |
| 52 Week Low | $8.28 | $3.93 |
| 52 Week High | $11.82 | $7.54 |
Technical Indicators
Market Signals| Indicator | GWRS | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 45.86 |
| Support Level | $8.35 | $4.87 |
| Resistance Level | $9.31 | $5.60 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 81.15 | 18.45 |
Price Performance
Historical ComparisonAbout GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.